quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

GreenCore Solutions Corp. (GSC) Ships CPG Knowledge Graph v3.2.0 -- AI Agents at 9.5 Million+ Monthly Transactions

View original at finance.yahoo.com
GreenCore Solutions Corp. (GSC) Ships CPG Knowledge Graph v3.2.0 -- AI Agents at 9.5 Million+ Monthly Transactions What's inside the CPG Knowledge Graph: Retail grocery — 3.29 million points of sale (POS) across 15,688 retail grocery banners and 38,350 brands in 50 global markets…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • From the end of 2026, roughly $3 trillion of annual grocery buying power sits behind AI Agent gates that speak only two open protocols: MCP and A2A.

    60% confidence
  • RAG-based competitor stacks typically take 3-5 months to reach production grade, with data preparation consuming 50-70% of the project budget before the first buyer query is answered.

    60% confidence
  • The CPG Knowledge Graph v3.2.0 is running at 3.7 AI Agent transactions every second — 220 a minute, 13,000+ an hour, 316,000+ a day, 9.5 million+ a month — held for three consecutive months (May, June, and July 2026), without a dollar of GSC advertising spend.

    60% confidence
  • GSC onboards BPC brands and private label SKUs to its AI Agents in 3-5 weeks, to production, not prototype.

    60% confidence
  • Machines now transact more than humans on the open internet.

    60% confidence

Data points we hold from this source

SAP SE · addressable grocery buying power3 trillion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com